Multicenter, randomized phase II study of neoadjuvant pembrolizumab plus chemotherapy and chemoradiotherapy in esophageal adenocarcinoma (EAC).

被引：13

作者：

Shah, Manish A.

Almhanna, Khaldoun

Iqbal, Syma

Thakkar, Prashant

Schneider, Bryan J.

Yantiss, Rhonda

Wu, Yiru

Futamura, Emma

Port, Jeffrey L.

Spinelli, Cathy

Sarkar, Sandipto

Christos, Paul J.

Brar, Gagandeep

Betel, Doron

Sanfilippo, Nicholas J.

Altorki, Nasser K.

机构：

[1] Weill Cornell Med, New York, NY USA

[2] Lifespan, Providence, RI USA

[3] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA

[4] Weill Cornell Med Coll, New York Presbyterian Hosp, New York, NY USA

[5] Weill Cornell Med, New York, NY USA

[6] Weill Cornell, New York, NY USA

[7] Lifespan Canc Inst, Providence, RI USA

[8] Cornell Univ, Weill Med Coll, New York, NY USA

[9] Weill Cornell Med Coll, New York, NY USA

[10] Weill Cornell Med Coll, Dept Biostat & Epidemiol, New York, NY USA

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.4005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4005

引用

页数：2